Talquetamab is highlighted in the EHA 2026 Plenary Abstract Session through S100 MonumenTAL-3, evaluating talquetamab…
Browsing: Life Science
Want to get ideas and solutions for your R&D in Life Science? Check out the resources powered by Patsnap Eureka, find the technical resources you need.
Ruxolitinib is included in the EHA 2026 entity workbook as a JAK1/2 inhibitor relevant to…
Selinexor is included in the EHA 2026 entity workbook as an XPO1 inhibitor relevant to…
Lenalidomide is included in the EHA 2026 entity workbook as an IMiD relevant to hematology…
SUCCESSOR-2 is an EHA 2026 late-breaking Phase 3 multiple myeloma study, listed as LB5004, evaluating…
Agios Pharmaceuticals is included for EHA 2026 market mapping because its portfolio or pipeline focus…
Astellas Pharma is included for EHA 2026 market mapping because its portfolio or pipeline focus…
Menin Inhibitor is included as an EHA 2026 modality keyword because it captures a recurring…
CELMoD is included as an EHA 2026 modality keyword because it captures a recurring technology…
Primary CNS Lymphoma is included as an EHA 2026 disease-area keyword under hematologic malignancy, with…